https://www.biospace.com/article/j-and-j-s-tremfya-shows-extended-success-in-treating-plaque-psoriasis/
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
www.PsoriasisTreatmentReport.com
https://www.biospace.com/article/j-and-j-s-tremfya-shows-extended-success-in-treating-plaque-psoriasis/
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-Phase-3-Psoriasis-Study-Meets-All-Endpoints-Achieving-Significantly-Greater-Efficacy-Versus-Placebo-and-Ustekinumab
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
https://clinicaltrials.gov/ct2/show/NCT04128007?type=Intr&cond=Psoriasis&lupd_s=10%2F02%2F2019&lupd_d=14
Condition : Plaque Psoriasis
Intervention : Drug: ARQ-154
Sponsor : Arcutis, Inc.
Not yet recruiting
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
NCT04128007
Wed, 16 Oct 2019 12:00:00 EDT
Last Update Posted: 10/16/19 08:20AM
https://www.jacionline.org/article/S0091-6749(19)31317-X/pdf
https://www.ncbi.nlm.nih.gov/pubmed/31622687?dopt=Abstract
IκBζ is a key player in the anti-psoriatic effects of secukinumab.
J Allergy Clin Immunol. 2019 Oct 14;:
Authors: Bertelsen T, Ljungberg C, Litman T, Huppertz C, Hennze R, Rønholt K, Iversen L, Johansen C
Abstract
BACKGROUND: IκBζ plays a key role in psoriasis by mediating IL-17A-driven effects, but the molecular mechanism by which IL-17A regulates IκBζ expression is not clarified.
OBJECTIVE: To explore the molecular transformation in psoriatic patients during anti-IL-17A (secukinumab) treatment with focus on IκBζ.
METHODS: The study was an open-label, one arm, single center secukinumab treatment study that included 14 patients with plaque psoriasis. Skin biopsies and blood samples were collected on day 0, 4, 14, 42 and 84; and processed for microarray gene expression analysis. Furthermore, in vitro experiments with human keratinocytes and synovial fibroblasts were conducted.
RESULTS: Secukinumab improved clinical scores and histological psoriasis features. Moreover, secukinumab altered the skin transcriptome. The major transcriptional shift appeared between day 14 and day 42 after treatment initiation, though already at day four, 80 genes were differentially expressed. NFKBIZ (the gene encoding IκBζ) was reduced already after four days of treatment in the skin. NFKBIZ expression correlated to PASI, and NFKBIZ mRNA levels in the skin decreased during anti-IL-17A treatment. Moreover, specific NFKBIZ signature genes were significantly altered during anti-IL-17A treatment. Finally, we identified Act1, p38 MAPK, JNK, and NF-κB as key signaling pathways in NFKBIZ/IκBζ regulation.
CONCLUSION: Our results define a crucial role for IκBζ in the anti-psoriatic effect of secukinumab. Because IκBζ signature genes were regulated already after four days of treatment, this strongly indicates that IκBζ plays a crucial role for the anti-psoriatic effects mediated by anti-IL-17A treatment.
PMID: 31622687 [PubMed – as supplied by publisher]
IκBζ is a key player in the anti-psoriatic effects of secukinumab.
PubMed:31622687
Last Update Posted: 10/18/19 06:03AM
https://www.mdlinx.com/journal-summaries/prospect-psoriasis-real-life-secukinumab-transition/2019/09/26/7580185/?spec=dermatology&rcid=38
Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study
https://www.mdpi.com/2073-4409/8/9/1089
https://www.ncbi.nlm.nih.gov/pubmed/31540162?dopt=Abstract
Related Articles
Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models.
Cells. 2019 Sep 15;8(9):
Authors: Chamcheu JC, Esnault S, Adhami VM, Noll AL, Banang-Mbeumi S, Roy T, Singh SS, Huang S, Kousoulas KG, Mukhtar H
Abstract
Psoriasis is a chronic immune-mediated skin disease that involves the interaction of immune and skin cells, and is characterized by cytokine-driven epidermal hyperplasia, deviant differentiation, inflammation, and angiogenesis. Because the available treatments for psoriasis have significant limitations, dietary products are potential natural sources of therapeutic molecules, which can repair the molecular defects associated with psoriasis and could possibly be developed for its management. Fisetin (3,7,3′,4′-tetrahydroxyflavone), a phytochemical naturally found in pigmented fruits and vegetables, has demonstrated proapoptotic and antioxidant effects in several malignancies. This study utilized biochemical, cellular, pharmacological, and tissue engineering tools to characterize the effects of fisetin on normal human epidermal keratinocytes (NHEKs), peripheral blood mononuclear cells (PBMC), and CD4+ T lymphocytes in 2D and 3D psoriasis-like disease models. Fisetin treatment of NHEKs dose- and time-dependently induced differentiation and inhibited interleukin-22-induced proliferation, as well as activation of the PI3K/Akt/mTOR pathway. Fisetin treatment of TNF-α stimulated NHEKs also significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2 (MAPK). In addition, fisetin treatment significantly decreased the secretion of Th1/Th-17 pro-inflammatory cytokines, particularly IFN-γ and IL-17A by 12-O-tetradecanolylphorbol 13-acetate (TPA)-stimulated NHEKs and anti-CD3/CD28-activated human PBMCs. Furthermore, we established the in vivo relevance of fisetin functions, using a 3D full-thickness human skin model of psoriasis (FTRHSP) that closely mimics in vivo human psoriatic skin lesions. Herein, fisetin significantly ameliorated psoriasis-like disease features, and decreased the production of IL-17 by CD4+ T lymphocytes co-cultured with FTRHSP. Collectively, our data identify the prodifferentiative, antiproliferative, and anti-inflammatory effects of fisetin, via modulation of the PI3K-Akt-mTOR and p38/JNK pathways and the production of cytokines in 2D and 3D human skin models of psoriasis. These results suggest that fisetin has a great potential to be developed as an effective and inexpensive agent for the treatment of psoriasis and other related inflammatory skin disorders.
PMID: 31540162 [PubMed – in process]
Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models.
PubMed:31540162
Last Update Posted: 09/22/19 06:04AM
https://www.health.com/condition/psoriasis/cbd-for-psoriasis
Can CBD Relieve Psoriasis Symptoms? Here’s What Doctors Are Saying
http://www.koreabiomed.com/news/articleView.html?idxno=5925
Lilly, AbbVie unveil new data for psoriasis treatment at global meet
https://clinicaltrials.gov/ct2/show/NCT03777436?type=Intr&cond=Psoriasis&lupd_s=04%2F17%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Apremilast; Other: Placebo
Sponsor : Celgene
Recruiting
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
NCT03777436
Mon, 17 Dec 2018 12:00:00 EST
Last Update Posted: 05/01/19 08:00AM
https://www.cnbc.com/2019/04/25/shares-of-bausch-health-formerly-known-as-valeant-rise-3percent-on-fda-approval-for-psoriasis-treatment.html
https://www.mdmag.com/medical-news/fda-approves-combination-lotion-plaque-psoriasis
https://clinicaltrials.gov/ct2/show/NCT03482011?type=Intr&cond=Psoriasis&lupd_s=04%2F11%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Mirikizumab; Drug: Placebo
Sponsor : Eli Lilly and Company
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03482011
Thu, 29 Mar 2018 12:00:00 EDT
Last Update Posted: 04/25/19 07:39AM
https://www.prnewswire.com/news-releases/abbvie-expands-immunology-portfolio-in-the-us-with-fda-approval-of-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis-300836934.html
https://clinicaltrials.gov/ct2/show/NCT03922607?type=Intr&cond=Psoriasis&lupd_s=04%2F08%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: ABBV-157; Drug: Placebo for ABBV-157
Sponsor : AbbVie
Not yet recruiting
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
NCT03922607
Mon, 22 Apr 2019 12:00:00 EDT
Last Update Posted: 04/22/19 08:43AM
https://www.nature.com/articles/s41435-019-0067-y
https://www.ncbi.nlm.nih.gov/pubmed/31000797?dopt=Abstract
Related Articles
The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies.
Genes Immun. 2019 Apr 19;:
Authors: Bianchi E, Rogge L
Abstract
Chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, spondyloarthritis, and psoriasis cause significant morbidity and are a considerable burden for the patients in terms of pain, impaired function, and diminished quality of life, as well as for society, because of the associated high health-care costs and loss of productivity. Our limited understanding of the pathogenic mechanisms involved in these diseases currently hinders early diagnosis and the development of more specific and effective therapies. The past years have been marked by considerable progress in our insight of the genetic basis of many diseases. In particular, genome-wide association studies (GWAS) performed with thousands of patients have provided detailed information about the genetic variants associated with a large number of chronic inflammatory diseases. These studies have brought to the forefront many genes linked to signaling pathways that were not previously known to be involved in pathogenesis, pointing to new directions in the study of disease mechanisms. GWAS also provided fundamental evidence for a key role of the immune system in the pathogenesis of these diseases, because many of the identified loci map to genes involved in different immune processes. However, the mechanisms by which disease-associated genetic variants act on disease development and the targeted cell populations remain poorly understood. The challenge of the post-GWAS era is to understand how these variants affect pathogenesis, to allow translation of genetic data into better diagnostics and innovative treatment strategies. Here, we review recent results that document the importance of the IL-23/IL-17 pathway for the pathogenesis of several chronic inflammatory diseases and summarize data that demonstrate how therapeutic targeting of this pathway can benefit affected patients.
PMID: 31000797 [PubMed – as supplied by publisher]
The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies.
PubMed:31000797
Last Update Posted: 04/20/19 06:04AM
https://www.sciencedirect.com/science/article/pii/S0896841119300241?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31005389?dopt=Abstract
CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by Vγ4+ γδ T cells.
J Autoimmun. 2019 Apr 18;:
Authors: Yue D, You Y, Zhang X, Wang B, Wang X, Qi R, Yang F, Meng X, Yoshikai Y, Wang Y, Sun X
Abstract
Psoriasis is a common, autoimmune, chronic inflammatory skin disease. It has been demonstrated that cutaneous T17 cells play an important pro-inflammatory role in the pathogenesis of psoriasis, through the production of various Th17-related cytokines. Our previous studies have demonstrated that CD30L/CD30 signal plays a pivotal role in the differentiation of CD4+ Th17 cells and Vγ6+γδ T17 cells in the gut-associated lymphoid tissues of mouse. However, its effect on the pathogenesis of psoriasis is unknown. Here, we fully prove that CD30L/CD30 signaling plays a novel protective role in the development of psoriasis in mice, through selective inhibition of CCR6 expression and Th17-related cytokine synthesis in the Vγ4+γδ T17 cell subset. Meanwhile, treatment with agonistic anti-CD30 mAb had a significant therapeutic effect on our psoriasis mouse model. Therefore, the CD30L/CD30 signaling pathway is an ideal target for antibody therapy, which may become a new approach for the immunobiological treatment of psoriasis.
PMID: 31005389 [PubMed – as supplied by publisher]
CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by Vγ4+ γδ T cells.
PubMed:31005389
Last Update Posted: 04/22/19 06:03AM
https://www.newswire.ca/news-releases/health-canada-approves-skyrizi-tm-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-852708327.html
https://clinicaltrials.gov/ct2/show/NCT03580278?type=Intr&cond=Psoriasis&lupd_s=04%2F04%2F2019&lupd_d=14
Condition : Psoriasis
Intervention : Biological: ABY-035/AFO2
Sponsor : Affibody
Not yet recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
NCT03580278
Mon, 09 Jul 2018 12:00:00 EDT
Last Update Posted: 04/18/19 08:23AM
https://clinicaltrials.gov/ct2/show/NCT03584360?type=Intr&cond=Psoriasis&lupd_s=04%2F04%2F2019&lupd_d=14
Condition : Psoriasis Vulgaris
Intervention : Drug: Betamethasone-Calcipotriene Topical
Sponsor : Centre Hospitalier Universitaire de Nice
Completed
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
NCT03584360
Thu, 12 Jul 2018 12:00:00 EDT
Last Update Posted: 04/18/19 08:23AM
https://www.ncbi.nlm.nih.gov/pubmed/30997975?dopt=Abstract
The efficacy and safety of targeted narrowband UVB therapy: a retrospective cohort study
Turk J Med Sci. 2019 Apr 18;49(2):595-603
Authors: Esen Salman K, Kıvanç Altunay İ, Salman A
Abstract
Background/aim: Phototherapy is a safe and effective treatment modality for numerous dermatological conditions. Recently, targeted phototherapy modalities have gained importance due to their advantages over conventional phototherapy.This retrospective study aimed to evaluate the safety and efficacy of targeted narrowband UVB phototherapy in patients with dermatological disorders
Materials and methods: This single-center study included 173 patients who were treated with targeted narrowband UVB phototherapy. Demographic features, phototherapy parameters, and adverse effects were evaluated in all patients, and the treatment response was assessed in patients who attended at least one follow-up visit.
Results: A total of 173 patients (102 females; 71 males) with vitiligo, alopecia areata, lichen simplex chronicus, palmoplantar psoriasis, and psoriasis vulgaris were included in the study. Among 73 patients, with whom the treatment was finalized by physician, an excellent response was obtained in 10%, 52.9%, 53.8%, 28.6%, and 40% of patients with vitiligo, alopecia areata, lichen simplex chronicus, palmoplantar psoriasis, and psoriasis, respectively. The treatment was generally well tolerated and was discontinued in only two patients due to adverse effects.
Conclusion: This study demonstrates that targeted narrowband UVB therapy is a safe and effective treatment alternative, particularly for alopecia areata, lichen simplex chronicus, and palmoplantar and plaque-type psoriasis.
PMID: 30997975 [PubMed]
The efficacy and safety of targeted narrowband UVB therapy: a retrospective cohort study
PubMed:30997975
Last Update Posted: 04/19/19 06:04AM
https://www.ncbi.nlm.nih.gov/pubmed/30993303?dopt=Abstract
Related Articles
A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars.
Clin Ter. 2019 Mar-Apr;170(2):e93-e99
Authors: Palmieri B, Laurino C, Vadalà M
Abstract
OBJECTIVE: To investigate the therapeutic effect of CBD-ointment administered on severe skin chronic diseases and/or on their outcome scars.
METHODS: A spontaneous, anecdotal, retrospective study of 20 patients with two most frequent skin disorders: psoriasis (n: 5 patients), atopic dermatitis (n: 5) and resulting outcome scars (n: 10). The subjects were instructed to administer topical CBD-enriched ointment to lesioned skin areas twice daily for three months treatment.
RESULTS: Based on skin evaluations (hydration, TEWL, elasticity), clinical questionnaires (SCORAD, ADI, PASI), and supported by photographic data and investigators’ clinical assessment, the results showed that topical treatment with CBD-enriched ointment significantly improved the skin parameters, the symptoms and also the PASI index score. No irritant or allergic reactions were documented during the period treatment.
CONCLUSIONS: The topical administration of CBD ointment, without any THC, is a safe and effective non-invasive alternative for improve the quality of life in patients with some skin disorders, especially on inflammatory background.
PMID: 30993303 [PubMed – in process]
A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars.
PubMed:30993303
Last Update Posted: 04/18/19 06:03AM
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.17989
https://www.ncbi.nlm.nih.gov/pubmed/30985920?dopt=Abstract
Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis.
Br J Dermatol. 2019 Apr 15;:
Authors: Langan EA, Künstner A, Miodovnik M, Zillikens D, Thaçi D, Baines JF, Ibrahim SM, Solbach W, Knobloch JK
Abstract
BACKGROUND: The treatment of psoriasis has been revolutionised by the development of biologic therapies. However, the pathogenesis of psoriasis, in particular the role of the cutaneous microbiome, remains incompletely understood. Moreover, skin microbiome studies have heavily relied on 16S rRNA sequencing data in the absence of bacterial culture.
OBJECTIVES: To characterise and compare the cutaneous microbiome in 20 healthy controls and 23 patients with psoriasis using metagenomic analyses and to determine changes in the microbiome during treatment.
METHODS: Swabs from lesional and non-lesional skin from psoriasis patients, and from site- and skin microenvironment matched controls, were analysed using both 16S rRNA sequencing and traditional culture combined with mass spectrometry (MALDI-TOF) in a prospective study.
RESULTS: Psoriasis was associated with an increased abundance of Firmicutes and a corresponding reduction in Actinobacteria, most marked in lesional skin, and at least partially reversed during systemic treatment. Shifts in bacterial community composition in lesional sites were reflected in similar changes in culturable bacteria, although changes in the microbiota over repeated swabbing were only detectable with sequencing. The composition of the microbial communities varied by skin site and microenvironment. Prevotella and Staphylococcus were significantly associated with lesional skin; Anaerococcus and Propionibacterium with non-lesional skin. There were no significant differences in the amount of bacteria cultured from the skin of healthy controls and psoriasis patients.
CONCLUSIONS: Shifts in the cutaneous microbiome in psoriasis, particularly during treatment, may shed new light on the pathogenesis of the disease and may be clinically exploited to predict treatment response. This article is protected by copyright. All rights reserved.
PMID: 30985920 [PubMed – as supplied by publisher]
Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis.
PubMed:30985920
Last Update Posted: 04/16/19 06:10AM
https://www.ncbi.nlm.nih.gov/pubmed/30972872?dopt=Abstract
Related Articles
Biologics for psoriasis: What is new?
Dermatol Ther. 2019 Apr 11;:e12916
Authors: Özyurt K, Ertaş R, Atasoy M
Abstract
Etiology of psoriasis is unclear but environmental, genetic, and immune factors act significant roles in the pathogenesis of this disease. Helper Tcells (TH), plasmoid and dermal dendritic cells play a prominent role in the development of classical psoriatic lesions. Interleukin stimulation is another important process in the pathogenesis of the disease that directly influences keratinocytes and leading to the formation of psoriatic pattern in the skin. Tumor necrosis factor (TNF) α which releases from keratinocytes activates dendritic cells in the early stages of complex pathogenesis of psoriasis. Activated keratinocytes produce also, other proinflammatory cytokines (IL-1b, and IL-6), antimicrobial peptides, and various chemokines. TNF activates dendritic cells that produce IL-23, leading to TH17 differentiation. TH17 cells secrete IL-17A, which has been shown to promote psoriatic skin changes. Consequently, after clarification of these main pathological mechanisms, anti-IL therapies have been accepted as a major treatment for patients with moderate-to severe psoriasis. Here, actual information will be presented about biological agents currently in clinical use or being tested for clinical application for treatment of patients with psoriasis. This article is protected by copyright. All rights reserved.
PMID: 30972872 [PubMed – as supplied by publisher]
Biologics for psoriasis: What is new?
PubMed:30972872
Last Update Posted: 04/12/19 06:00AM
https://onlinelibrary.wiley.com/doi/full/10.1002/kjm2.12034
https://www.ncbi.nlm.nih.gov/pubmed/30942529?dopt=Abstract
Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway.
Kaohsiung J Med Sci. 2019 Apr 03;:
Authors: Chen JG, Fan HY, Wang T, Lin LY, Cai TG
Abstract
Psoriasis is a multisystem disease affecting about 2% of the population, while keratin16 (KRT16) has been reported to participate in psoriasis. However, the specific mechanism of KRT16 in psoriasis was inadequately investigated. The objective of the study was to elucidate the mechanism by which siRNA-mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal-related kinase (ERK) signaling pathway. Psoriasis-related core gene KRT16 was screened out. Then, the expression of KRT16, VEGF, and ERK signaling pathway-related genes was detected in psoriatic patients. To further investigate the mechanism of KRT16, keratinocytes in psoriatic patients were treated with KRT16 siRNA or/and ERK inhibitor (PD98059) to detect the changes in related gene expression and cell survival. KRT16 was involved in psoriasis development. The expression levels of KRT16, p-ERK1/2, and VEGF in lesion tissues are significantly elevated. Keratinocytes treated with KRT16-siRNA and KRT16-siRNA + PD98059 exhibited reduced KRT16, p-ERK1/2, and VEGF expression. The cell survival rate in cells treated with KRT16-siRNA, PD98059, and KRT16-siRNA + PD98059 reduced significantly. These findings indicate that silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway, which provides a basic theory in the treatment of psoriasis.
PMID: 30942529 [PubMed – as supplied by publisher]
Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway.
PubMed:30942529
Last Update Posted: 04/04/19 06:04AM
https://clinicaltrials.gov/ct2/show/NCT02896868?type=Intr&cond=Psoriasis&lupd_s=03%2F20%2F2019&lupd_d=14
Conditions : Skin Diseases; Psoriasis
Interventions : Drug: LY3041658; Drug: Placebo
Sponsor : Eli Lilly and Company
Active, not recruiting
A Study of LY3041658 in Participants With Skin Diseases
NCT02896868
Mon, 12 Sep 2016 12:00:00 EDT
Last Update Posted: 04/03/19 07:43AM
https://clinicaltrials.gov/ct2/show/NCT03611751?type=Intr&cond=Psoriasis&lupd_s=03%2F20%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: BMS-986165; Other: Placebo; Drug: Apremilast
Sponsor : Bristol-Myers Squibb
Recruiting
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751
Thu, 02 Aug 2018 12:00:00 EDT
Last Update Posted: 04/03/19 07:43AM
https://clinicaltrials.gov/ct2/show/NCT03718884?type=Intr&cond=Psoriasis&lupd_s=03%2F20%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Drug Cocktail; Drug: Mirikizumab
Sponsor : Eli Lilly and Company
Recruiting
A Study of Mirikizumab in Participants With Plaque Psoriasis
NCT03718884
Thu, 25 Oct 2018 12:00:00 EDT
Last Update Posted: 04/03/19 07:43AM
https://link.springer.com/article/10.1007%2Fs40257-019-00434-w
https://www.ncbi.nlm.nih.gov/pubmed/30941636?dopt=Abstract
Related Articles
Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis.
Am J Clin Dermatol. 2019 Apr 02;:
Authors: Skoie IM, Dalen I, Omdal R
Abstract
BACKGROUND: Fatigue is frequent in patients with psoriasis. Though conventional drugs in general have no effect on fatigue, biological agents have demonstrated beneficial effects in several other chronic inflammatory diseases.
OBJECTIVE: The objective of the present study was to evaluate the effect of biological drugs on fatigue in patients with psoriasis vulgaris.
METHODS: We conducted a meta-analysis of randomized controlled trials in which anti-interleukin-12/23, anti-interleukin-23, anti-interleukin-17, or anti-tumor necrosis factor-α agents were used for psoriasis vulgaris and fatigue was an outcome measure.
RESULTS: A total of eight randomized controlled trials fulfilled criteria for inclusion in the meta-analysis. The studies used two fatigue reporting scales: the Functional Assessment of Chronic Illness Therapy-Fatigue and the Short Form 36 Health Survey Vitality Subscale. Treatment by biological agents in general compared with placebo led to a significant reduction in fatigue, with a standardized mean difference of - 0.40 (95% confidence interval - 0.46 to - 0.34; p < 0.001). CONCLUSION: Biological drugs used for the treatment of psoriasis vulgaris have a consistently small-to-moderate beneficial effect on fatigue independent of the type of drug. PMID: 30941636 [PubMed - as supplied by publisher] Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis. PubMed:30941636 Last Update Posted: 04/04/19 06:04AM
https://www.globenewswire.com/news-release/2019/04/02/1794808/0/en/Novartis-first-in-class-Cosentyx-approved-in-China-for-psoriasis-patients.html
https://clinicaltrials.gov/ct2/show/NCT03898583?type=Intr&cond=Psoriasis&lupd_s=03%2F19%2F2019&lupd_d=14
Condition : Psoriasis Vulgaris
Interventions : Drug: Microarray patch A; Drug: Microarray patch B; Drug: Placebo; Drug: Daivobet
Sponsor : LEO Pharma
Not yet recruiting
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
NCT03898583
Tue, 02 Apr 2019 12:00:00 EDT
Last Update Posted: 04/02/19 08:12AM
https://clinicaltrials.gov/ct2/show/NCT02607774?type=Intr&cond=Psoriasis&lupd_s=03%2F19%2F2019&lupd_d=14
Condition : Moderate to Severe Plaque Psoriasis
Interventions : Drug: Midazolam; Drug: AIN457
Sponsor : Novartis Pharmaceuticals
Completed
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
NCT02607774
Wed, 18 Nov 2015 12:00:00 EST
Last Update Posted: 04/02/19 08:12AM
https://clinicaltrials.gov/ct2/show/NCT03896581?type=Intr&cond=Psoriasis&lupd_s=03%2F18%2F2019&lupd_d=14
Condition : Psoriatic Arthritis
Interventions : Drug: Bimekizumab; Other: Placebo
Sponsor : UCB Biopharma S.P.R.L.
Not yet recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
NCT03896581
Mon, 01 Apr 2019 12:00:00 EDT
Last Update Posted: 04/01/19 08:48AM
https://clinicaltrials.gov/ct2/show/NCT03897088?type=Intr&cond=Psoriasis&lupd_s=03%2F18%2F2019&lupd_d=14
Condition : Scalp Psoriasis
Interventions : Drug: Tildrakizumab; Drug: Placebo
Sponsor : Sun Pharma Global FZE
Not yet recruiting
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasi
NCT03897088
Mon, 01 Apr 2019 12:00:00 EDT
Last Update Posted: 04/01/19 08:48AM
https://clinicaltrials.gov/ct2/show/NCT03897075?type=Intr&cond=Psoriasis&lupd_s=03%2F18%2F2019&lupd_d=14
Conditions : Chronic Plaque Psoriasis; Moderate to Severe Nail Psoriasis
Interventions : Drug: Tildrakizumab; Drug: Placebo
Sponsor : Sun Pharma Global FZE
Not yet recruiting
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
NCT03897075
Mon, 01 Apr 2019 12:00:00 EDT
Last Update Posted: 04/01/19 08:48AM
https://link.springer.com/article/10.1007%2Fs10787-019-00589-2
https://www.ncbi.nlm.nih.gov/pubmed/30929155?dopt=Abstract
Are peptides a solution for the treatment of hyperactivated JAK3 pathways?
Inflammopharmacology. 2019 Mar 30;:
Authors: Dullius A, Rocha CM, Laufer S, de Souza CFV, Goettert MI
Abstract
While the inactivation mutations that eliminate JAK3 function lead to the immunological disorders such as severe combined immunodeficiency, activation mutations, causing constitutive JAK3 signaling, are known to trigger various types of cancer or are responsible for autoimmune diseases, such as rheumatoid arthritis, psoriasis, or inflammatory bowel diseases. Treatment of hyperactivated JAK3 is still an obstacle, due to different sensibility of mutation types to conventional drugs and unwanted side effects, because these drugs are not absolutely specific for JAK3, thus inhibiting other members of the JAK family, too. Lack of information, in which way sole inhibition of JAK3 is necessary for elimination of the disease, calls for the development of isoform-specific JAK3 inhibitors. Beside this strategy, up to date peptides are a rising alternative as chemo- or immunotherapeutics, but still sparsely represented in drug development and clinical trials. Beyond a possible direct inhibition function, crossing the cancer cell membrane and interfering in disease-causing pathways or triggering apoptosis, peptides could be used in future as adjunct remedies to potentialize traditional therapy and preserve non-affected cells. To discuss such feasible topics, this review deals with the knowledge about the structure-function of JAK3 and the actual state-of-the-art of isoform-specific inhibitor development, as well as the function of currently approved drugs or those currently being tested in clinical trials. Furthermore, several strategies for the application of peptide-based drugs for cancer therapy and the physicochemical and structural relations to peptide efficacy are discussed, and an overview of peptide sequences, which were qualified for clinical trials, is given.
PMID: 30929155 [PubMed – as supplied by publisher]
Are peptides a solution for the treatment of hyperactivated JAK3 pathways?
PubMed:30929155
Last Update Posted: 04/01/19 06:02AM
https://www.nature.com/articles/s41598-019-41655-7
https://www.ncbi.nlm.nih.gov/pubmed/30926837?dopt=Abstract
Related Articles
Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation.
Sci Rep. 2019 Mar 29;9(1):5310
Authors: Wang Y, Edelmayer R, Wetter J, Salte K, Gauvin D, Leys L, Paulsboe S, Su Z, Weinberg I, Namovic M, Gauld SB, Honore P, Scott VE, McGaraughty S
Abstract
Psoriasis is an immune-mediated inflammatory skin disease that affects millions worldwide. Studying immune cells involved in psoriasis pathogenesis is essential to identify effective and safe therapeutics for the disease. Using human psoriasis skin, activated macrophages were observed in both lesional and non-lesional skin, but were elevated in lesional skin. Activation of the IL-23/IL-17 pathway is integral to the development of psoriasis. To further characterize the monocyte/macrophage (Mon/Mac) population when the IL-23 pathway is activated, a murine model of intradermal injection of IL-23 was used. Flow cytometry revealed that Mon/Mac cells were the dominant immune population, particularly late in the model, highlighted by strong presence of Ly6ChiMHC IIhi cells. The Mon/Mac cells were also shown to have high expression for TNFα but not IL-17A. Prophylactic dosing of a CSF-1R inhibitor to deplete Mon/Mac cells significantly reduced several inflammatory mediators from the skin tissue suggesting a pathogenic role for Mon/Mac. Treatment dosing of the inhibitor produced a less robust effect. Mon/Mac cells were also differentiated by levels of Ki67 and TNFα expression. These data point to an important contribution of Mon/Mac cells in IL-23 related skin inflammation and suggest that these cells are a significant player in the underlying pathophysiology of psoriasis.
PMID: 30926837 [PubMed – in process]
Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation.
PubMed:30926837
Last Update Posted: 03/31/19 06:04AM
https://clinicaltrials.gov/ct2/show/NCT03895203?type=Intr&cond=Psoriasis&lupd_s=03%2F15%2F2019&lupd_d=14
Condition : Psoriatic Arthritis
Interventions : Drug: Bimekizumab; Drug: Adalimumab; Other: Placebo
Sponsor : UCB Biopharma S.P.R.L.
Not yet recruiting
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
NCT03895203
Fri, 29 Mar 2019 12:00:00 EDT
Last Update Posted: 03/29/19 09:49AM
https://clinicaltrials.gov/ct2/show/NCT03895372?type=Intr&cond=Psoriasis&lupd_s=03%2F15%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: PF-06826647 or Placebo; Drug: PF-06826647
Sponsor : Pfizer
Not yet recruiting
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
Fri, 29 Mar 2019 12:00:00 EDT
Last Update Posted: 03/29/19 09:49AM
https://www.ncbi.nlm.nih.gov/pubmed/30928971?dopt=Abstract
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
Dermatology. 2019 Mar 29;:1-6
Authors: Chiricozzi A, Conti A, Burlando M, Odorici G, Gaiani F, Panduri S, Malagoli P
Abstract
BACKGROUND: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported.
METHODS: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients.
RESULTS: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (> 2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs.
CONCLUSION: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.
PMID: 30928971 [PubMed – as supplied by publisher]
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
PubMed:30928971
Last Update Posted: 04/01/19 06:02AM
https://www.sciencedirect.com/science/article/pii/S1567576918309056?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/30933843?dopt=Abstract
Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms.
Int Immunopharmacol. 2019 Mar 29;71:301-312
Authors: Sunkari S, Thatikonda S, Pooladanda V, Challa VS, Godugu C
Abstract
The purpose of this study was to investigate the protective effects of ambroxol in psoriasis-like skin inflammation both in vitro and in vivo and delineate the molecular mechanism of ambroxol. Our data demonstrated that ambroxol has an imperative role in inhibiting the lipopolysaccharide (LPS) stimulated nitrite levels, total cellular and mitochondrial reactive oxygen species level which was determined by Griess assay, DCFDA, and MitoSOX Red staining, respectively. We found that ambroxol remarkably reduced imiquimod (IMQ) induced epidermal hyperplasia, psoriasis area and severity index (PASI) scoring, splenomegaly, skin, and ear fold thickness. In addition, the histopathological evaluation revealed that ambroxol topical and subcutaneous treatment eloquently reduced psoriasiform lesions including acanthosis. Moreover, with ambroxol intervention, the levels of antioxidants glutathione (GSH), superoxide dismutase (SOD), and IL-10 were found to be increased along with a reduction in nitrite levels in skin tissues. On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1β, IL-6, IL-17, IL-22, IL-23, TGF-β, and TNF-α. Furthermore, from immunoblotting, we found a decrease in the protein expression of nitrotyrosine, iNOS, NF-κB and MAPKs signaling cascade with a concomitant increase in the expression of Nrf-2 and SOD-1 in RAW 264.7 cells and skin tissues by ambroxol. Similar findings were observed by immunofluorescence in macrophages. Moreover, ambroxol downregulated the ICAM-1 and Ki67 expression observed in skin tissues. Collectively, our results demonstrate that ambroxol may have intriguing therapeutic possibilities in attenuating psoriasis.
PMID: 30933843 [PubMed – as supplied by publisher]
Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms.
PubMed:30933843
Last Update Posted: 04/02/19 06:01AM
https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1582896
https://www.ncbi.nlm.nih.gov/pubmed/30919721?dopt=Abstract
Choice Overload in Systemic Psoriasis Therapy.
J Dermatolog Treat. 2019 Mar;30(2):103-104
Authors: Whitman PA, Cline AE, Feldman SR
PMID: 30919721 [PubMed – in process]
Choice Overload in Systemic Psoriasis Therapy.
PubMed:30919721
Last Update Posted: 03/29/19 06:01AM
https://clinicaltrials.gov/ct2/show/NCT02698475?type=Intr&cond=Psoriasis&lupd_s=03%2F14%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Ustekinumab 0.75 mg/kg; Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg
Sponsor : Janssen Research & Development, LLC
Active, not recruiting
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
NCT02698475
Thu, 03 Mar 2016 12:00:00 EST
Last Update Posted: 03/28/19 09:26AM
https://clinicaltrials.gov/ct2/show/NCT03894579?type=Intr&cond=Psoriasis&lupd_s=03%2F14%2F2019&lupd_d=14
Condition : Moderate to Severe Plaque Psoriasis
Intervention : Biological: Study Product: SNK01
Sponsor : NKMax America, Inc.
Recruiting
Autologous Natural Killer Cells in Subjects With Moderate to Severe Psoriasis
NCT03894579
Thu, 28 Mar 2019 12:00:00 EDT
Last Update Posted: 03/28/19 09:26AM
https://www.biospectrumasia.com/news/28/13108/abbvie-gets-the-first-global-regulatory-approval-of-skyrizi-in-japan.html
https://www.ncbi.nlm.nih.gov/pubmed/30926369?dopt=Abstract
https://www.jaad.org/article/S0190-9622(19)30500-6/pdf
Related Articles
A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody®, in moderate-to-severe psoriasis.
J Am Acad Dermatol. 2019 Mar 26;:
Authors: Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG
Abstract
BACKGROUND: Interleukin 17 (IL-17) is involved in the pathogenesis of psoriasis, a chronic, debilitating disease.
OBJECTIVES: To evaluate safety/tolerability, immunogenicity, pharmacokinetics/pharmacodynamics and efficacy of M1095 (ALX-0761), an anti-IL-17A/F Nanobody®, in moderate-to-severe plaque psoriasis.
METHODS: This multicenter, double-blind, placebo-controlled dose-escalation phase 1 study randomized 44 patients 4:1 to subcutaneous M1095 (30, 60, 120, or 240 mg) or placebo bi-weekly for 6 weeks, in 4 ascending dose cohorts.
RESULTS: The most frequent treatment-emergent adverse events (AEs) with M1095 were pruritus (n=4) and headache (n=3); two patients withdrew due to AEs (injection site reaction, and elevated liver enzymes). Terminal half-life of M1095 was 11-12 days. AUC/Cmax was dose-proportional. Five of 10 M1095-treated patients (positive for anti-drug antibodies) showed treatment-emergent anti-drug antibody responses with no effect on M1095 exposure. Marked decreases in psoriasis inflammatory markers were observed with M1095. By Day 85, 100% and 56% of patients receiving M1095 240 mg achieved psoriasis area and severity index 90 and 100, respectively. Improvements in static physician’s global assessment, and affected body surface area were also seen.
LIMITATIONS: Interpretation of efficacy data is limited by the small sample size.
CONCLUSION: Multiple subcutaneous doses of M1095 showed a favorable safety profile with dose-dependent improvements in psoriasis.
PMID: 30926369 [PubMed – as supplied by publisher]
A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody®, in moderate-to-severe psoriasis.
PubMed:30926369
Last Update Posted: 03/31/19 06:04AM
https://www.prnewswire.com/news-releases/abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-erythrodermic-psoriasis-and-psoriatic-arthritis-in-japan-300818288.html
https://clinicaltrials.gov/ct2/show/NCT01729754?type=Intr&cond=Psoriasis&lupd_s=03%2F12%2F2019&lupd_d=14
Condition : Plaque Psoriasis
Interventions : Drug: Tildrakizumab 200 mg; Drug: Tildrakizumab 100 mg; Drug: Tildrakizumab Placebo; Drug: Etanercept Placebo; Drug: Etanercept 50 mg
Sponsor : Sun Pharma Global FZE
Active, not recruiting
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754
Tue, 20 Nov 2012 12:00:00 EST
Last Update Posted: 03/26/19 09:35AM
https://www.newswire.ca/news-releases/health-canada-approves-cimzia-r-certolizumab-pegol-for-moderate-to-severe-psoriasis-883050362.html
https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.13917
https://www.ncbi.nlm.nih.gov/pubmed/30903711?dopt=Abstract
Related Articles
Imiquimod-induced skin inflammation is relieved by knockdown of sodium channel Nax.
Exp Dermatol. 2019 Mar 23;:
Authors: Zhao J, Xie P, Galiano RD, Qi S, Mao R, Mustoe TA, Hong SJ
Abstract
Nax is an atypical sodium channel that mediates inflammatory pathways in pathological conditions of the skin. In this study, we developed a skin inflammation model in the rabbit ear through application of imiquimod (IMQ). Knockdown of Nax using RNAi attenuated IMQ-induced skin inflammation, including skin erythema, scaling, and papule formation. Histologic analysis showed that thickening and insufficient differentiation of the epidermis found in psoriasis-like skin were normalized by administration of Nax -RNAi. Excessive infiltration of inflammatory cells found in inflammatory lesions, such as mast cells, eosinophils, neutrophils, T cells, and macrophages, was reduced by Nax -RNAi. Expression of S100A9, which is a downstream gene of Nax and a mediator of inflammation, was decreased by Nax -RNAi. Our results demonstrated that knockdown of Nax ameliorated IMQ-induced psoriasis-like skin inflammation in vivo. Thus, targeting of Nax may represent a potential therapeutic option for the treatment of psoriasis. This article is protected by copyright. All rights reserved.
PMID: 30903711 [PubMed – as supplied by publisher]
Imiquimod-induced skin inflammation is relieved by knockdown of sodium channel Nax.
PubMed:30903711
Last Update Posted: 03/25/19 01:15PM
https://www.mdpi.com/1422-0067/20/6/1475
https://www.ncbi.nlm.nih.gov/pubmed/30909615?dopt=Abstract
Related Articles
Psoriasis Pathogenesis and Treatment.
Int J Mol Sci. 2019 Mar 23;20(6):
Authors: Rendon A, Schäkel K
Abstract
Research on psoriasis pathogenesis has largely increased knowledge on skin biology in general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis have been translated into targeted and highly effective therapies providing fundamental insights into the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis. This review discusses the mechanisms involved in the initiation and development of the disease, as well as the therapeutic options that have arisen from the dissection of the inflammatory psoriatic pathways. Our discussion begins by addressing the inflammatory pathways and key cell types initiating and perpetuating psoriatic inflammation. Next, we describe the role of genetics, associated epigenetic mechanisms, and the interaction of the skin flora in the pathophysiology of psoriasis. Finally, we include a comprehensive review of well-established widely available therapies and novel targeted drugs.
PMID: 30909615 [PubMed – in process]
Psoriasis Pathogenesis and Treatment.
PubMed:30909615
Last Update Posted: 03/27/19 06:02AM
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25470
https://www.ncbi.nlm.nih.gov/pubmed/30900768?dopt=Abstract
Curative Potential of Hematopoietic Stem Cell Transplantation for Advanced Psoriasis.
Am J Hematol. 2019 Mar 22;:
Authors: Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin RE
PMID: 30900768 [PubMed – as supplied by publisher]
Curative Potential of Hematopoietic Stem Cell Transplantation for Advanced Psoriasis.
PubMed:30900768
Last Update Posted: 03/23/19 06:01AM
https://clinicaltrials.gov/ct2/show/NCT03671148?type=Intr&cond=Psoriasis&lupd_s=03%2F08%2F2019&lupd_d=14
Condition : Psoriatic Arthritis
Interventions : Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor : AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148
Fri, 14 Sep 2018 12:00:00 EDT
Last Update Posted: 03/22/19 09:27AM
https://clinicaltrials.gov/ct2/show/NCT01976364?type=Intr&cond=Psoriasis&lupd_s=03%2F08%2F2019&lupd_d=14
Condition : Arthritis, Psoriatic
Interventions : Drug: Tofacitinib; Drug: Methotrexate; Drug: Placebo Methotrexate
Sponsor : Pfizer
Active, not recruiting
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
NCT01976364
Tue, 05 Nov 2013 12:00:00 EST
Last Update Posted: 03/22/19 09:27AM
https://clinicaltrials.gov/ct2/show/NCT03370133?type=Intr&cond=Psoriasis&lupd_s=03%2F08%2F2019&lupd_d=14
Conditions : Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis; Psoriatic Arthritis
Interventions : Drug: Bimekizumab; Drug: Ustekinumab; Other: Placebo
Sponsor : UCB Biopharma S.P.R.L.
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03370133
Tue, 12 Dec 2017 12:00:00 EST
Last Update Posted: 03/22/19 09:27AM
https://clinicaltrials.gov/ct2/show/NCT03726489?type=Intr&cond=Psoriasis&lupd_s=03%2F08%2F2019&lupd_d=14
Conditions : Psoriasis; Psoriatic Plaque
Interventions : Device: Daavlin 7 series 3 panel narrow band phototherapy home units; Device: narrow band phototherapy clinic units
Sponsors : University of Pennsylvania; University of Utah; National Psoriasis Foundation; Patient-Centered Outcomes Research Institute
Recruiting
Light Treatment Effectiveness (LITE) Study
NCT03726489
Wed, 31 Oct 2018 12:00:00 EDT
Last Update Posted: 03/22/19 09:27AM
https://www.biospace.com/article/releases/durect-announces-patient-dosing-in-phase-2a-proof-of-concept-clinical-trial-of-topical-dur-928-in-patients-with-mild-to-moderate-plaque-psoriasis/
http://investors.durect.com/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=2391958
https://www.tandfonline.com/doi/abs/10.1080/08982104.2019.1593449?journalCode=ilpr20
https://www.ncbi.nlm.nih.gov/pubmed/30897993?dopt=Abstract
Related Articles
Preparation, Characterization and In Vivo Evaluation of Cyclosporine Cationic Liposomes for the Treatment of Psoriasis.
J Liposome Res. 2019 Mar 21;:1-25
Authors: Walunj M, Doppalapudi S, Bulbake U, Khan W
Abstract
Cyclosporine (CYC), a calcineurin inhibitor acts specifically on T-cells and is one of the most effective treatment options for psoriasis. Systemic administration of the drug has been associated with dose-dependent toxic effects, while its topical delivery is a challenging task due to unfavourable physicochemical properties of drug. The aim of the present study is to develop and evaluate the efficacy of topical liposomal gel containing CYC loaded cationic liposomal nanocarriers in imiquimod induced psoriatic plaque model. Liposomes composed of DOTAP and cholesterol was formulated by different liposomal preparation techniques. Optimized liposomal carriers prepared by ethanol injection method were characterized with respect to size, zeta potential, entrapment efficiency, stability, in vitro drug release and in vivo studies. Cationic liposomes with particle size of 111 ± 1.62 nm, PDI of 0.27 ± 0.08, entrapment efficiency of 93 ± 2.12% and zeta potential of 41.12 ± 3.56 mV were obtained. Drug loaded liposomal gels showed shear thinning behaviour, which is suitable for topical application. Topical application of CYC liposomal gels on imiquimod induced psoriatic plaque model reduced the symptoms of psoriasis and levels of key psoriatic cytokines such as tumor necrosis factor-α, IL-17 and IL-22. In conclusion, the developed liposomal carrier of CYC was found to be effective and can find application in treatment of psoriasis.
PMID: 30897993 [PubMed – as supplied by publisher]
Preparation, Characterization and In Vivo Evaluation of Cyclosporine Cationic Liposomes for the Treatment of Psoriasis.
PubMed:30897993
Last Update Posted: 03/23/19 06:01AM
https://www.nature.com/articles/s41419-019-1510-8
https://www.ncbi.nlm.nih.gov/pubmed/30894513?dopt=Abstract
Related Articles
Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.
Cell Death Dis. 2019 Mar 20;10(4):274
Authors: Sun S, Zhang X, Xu M, Zhang F, Tian F, Cui J, Xia Y, Liang C, Zhou S, Wei H, Zhao H, Wu G, Xu B, Liu X, Yang G, Wang Q, Zhang L, Gong Y, Shao C, Zou Y
Abstract
Psoriasis is a chronic skin disease characterized by hyperproliferation and impaired differentiation of epidermal keratinocytes accompanied by increased inflammation, suggesting that molecules with antiproliferation and anti-inflammatory abilities may be effective for its treatment. One of the key steps in regulating cell proliferation is DNA replication initiation, which relies on prereplication complex (pre-RC) assembly on chromatin. CDC6 is an essential regulator of pre-RC assembly and DNA replication in eukaryotic cells, but its role in proliferation of keratinocytes and psoriasis is unknown. Here we examined CDC6 expression in psoriatic skin and evaluated its function in the proliferation of human keratinocytes. CDC6 expression is upregulated in epidermal cells in psoriatic lesions and it could be induced by IL-22/STAT3 signaling, a key signaling pathway involved in the pathogenesis of psoriasis, in keratinocytes. Depletion of CDC6 leads to decreased proliferation of keratinocytes. We also revealed that berberine (BBR) could inhibit CDK4/6-RB-CDC6 signaling in keratinocytes, leading to reduced proliferation of keratinocytes. The mechanism of antiproliferation effects of BBR is through the repression of JAK1, JAK2, and TYK2, which in turn inhibits activation of STAT3. Finally, we demonstrated that BBR could inhibit imiquimod-induced psoriasis-like skin lesions and upregulation of CDC6 and p-STAT3 in mice. Collectively, our findings indicate that BBR inhibits CDC6 expression and proliferation in human keratinocytes by interfering the JAK-STAT3 signaling pathway. Thus, BBR may serve as a potential therapeutic option for patients with psoriasis.
PMID: 30894513 [PubMed – in process]
Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.
PubMed:30894513
Last Update Posted: 03/22/19 06:03AM
https://www.ncbi.nlm.nih.gov/pubmed/30957038?dopt=Abstract
Related Articles
Dendrimer entrapped microsponge gel of dithranol for effective topical treatment.
Heliyon. 2019 Mar;5(3):e01343
Authors: Tripathi PK, Gorain B, Choudhury H, Srivastava A, Kesharwani P
Abstract
Dithranol is one of the important topical agents for the treatment of psoriasis, a chronic inflammatory skin disease with aberrant differentiation of keratinocytes. However, its application is troublesome and inconvenient because of its associated side effects, including staining, burning sensation, irritation, and necrotizing effect on the diseased cells as well as on the normal cells. The purpose of the current investigation was to explore the potential of poly(amido) amine (PAMAM) dendrimers in the topical delivery of dithranol through a novel microsponge based gel. Generation-4 (G4) dendrimers were incorporated into the microsponge based gel formulation by quasi-emulsion solvent diffusion method with varying concentration of polymers, and evaluated for the morphology of the formulation, encapsulation efficiency and skin irritation potential. Percentage yield of the formulation was found to be 66.28%, whereas encapsulation efficiency was ranged between 71.33% to 49.21%, and an average particle size was ranged between 28 ± 1.12 μm to 130 ± 1.01 μm. Surface morphology of developed microsponge was confirmed by scanning electron microscopy, revealed micro-porous nature. The optimized microsponge formulation was found to be stable and recorded non-irritant during cutaneous application of the experimental animals. Further, the pharmacokinetic outcomes of study were showed prolong penetration of the drug through the skin, equivalent to the marketed formulation of dithranol. Therefore, it could be conferred that the microsponge formulation of the PAMAM entrapped dithranol can produce prolonged efficacy without producing toxicities to the skin, and thus can effectively be projected in the treatment of diseases like psoriasis.
PMID: 30957038 [PubMed]
Dendrimer entrapped microsponge gel of dithranol for effective topical treatment.
PubMed:30957038
Last Update Posted: 04/09/19 07:04AM
https://insights.ovid.com/crossref?an=00005792-201903150-00003
https://www.ncbi.nlm.nih.gov/pubmed/30882619?dopt=Abstract
Effect of Korean medicine as add-on therapy to phototherapy for psoriasis: Two case reports.
Medicine (Baltimore). 2019 Mar;98(11):e14526
Authors: Lee SR, Kim S, Park CE, Lee JH, Lee DH
Abstract
RATIONALE: Psoriasis is a common chronic, immune-mediated inflammatory skin disease. Here, we describe 2 patients who presented with psoriasis to illustrate the potential efficacy of Korean medicine treatment combined with phototherapy.
PATIENT CONCERNS: A 33-year-old female (Case 1) and a 37-year-old male (Case 2) presented at the clinic with symptoms of itching, erythema, and scaliness.
DIAGNOSIS: Both patients were diagnosed with psoriasis based on the locations of erythema, as well as the appearance of circumscribed scaly papules and plaques.
INTERVENTIONS: Patients underwent 5 months (Case 1) and 8 months (Case 2) of treatments with acupuncture, herbal medicine, probiotics, and phototherapy.
OUTCOMES: After treatment, the patients improved in Psoriasis Area and Severity Index score from 7 to 1.2 (Case 1), and 23.2 to 2.2 (Case 2).
LESSONS: These outcomes suggest that Korean medicine therapies combined with phototherapy may be effective for resolution of psoriasis; however, further research is needed to confirm these findings.
PMID: 30882619 [PubMed – in process]
Effect of Korean medicine as add-on therapy to phototherapy for psoriasis: Two case reports.
PubMed:30882619
Last Update Posted: 03/19/19 06:02AM
https://www.ncbi.nlm.nih.gov/pubmed/30879102?dopt=Abstract
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
Arch Dermatol Res. 2019 Mar 16;:
Authors: Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K, Puig L, Hoetzenecker W, Schütz-Bergmayr M, Weger W, Wolf P, Reider N, Ratzinger G, Papageorgiou K, Meier TO, Maul JT, Anzengruber F, Navarini AA
Abstract
IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.
PMID: 30879102 [PubMed – as supplied by publisher]
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
PubMed:30879102
Last Update Posted: 03/18/19 06:05AM
https://clinicaltrials.gov/ct2/show/NCT03478787?type=Intr&cond=Psoriasis&lupd_s=03%2F01%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: risankizumab; Drug: secukinumab
Sponsor : AbbVie
Active, not recruiting
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
NCT03478787
Tue, 27 Mar 2018 12:00:00 EDT
Last Update Posted: 03/15/19 11:32AM
https://clinicaltrials.gov/ct2/show/NCT03874975?type=Intr&cond=Psoriasis&lupd_s=02%2F28%2F2019&lupd_d=14
Condition : Psoriasis Vulgaris
Intervention : Drug: oral vitamin D
Sponsor : Assiut University
Not yet recruiting
Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris
NCT03874975
Thu, 14 Mar 2019 12:00:00 EDT
Last Update Posted: 03/14/19 09:46AM
Examining the Potential Benefits of Secukinumab in Palmoplantar Pustular Psoriasis Treatment
Examining the Potential Benefits of Secukinumab in Palmoplantar Pustular Psoriasis Treatment
https://clinicaltrials.gov/ct2/show/NCT03701763?type=Intr&cond=Psoriasis&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Apremilast (CC-10004); Other: Placebo
Sponsor : Celgene
Recruiting
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NCT03701763
Wed, 10 Oct 2018 12:00:00 EDT
Last Update Posted: 03/13/19 10:17AM
https://www.jidonline.org/article/S0022-202X(19)31316-8/pdf
https://www.ncbi.nlm.nih.gov/pubmed/30878677?dopt=Abstract
Cis-khellactone inhibited the proinflammatory macrophages via promoting autophagy to ameliorate imiquimod-induced psoriasis.
J Invest Dermatol. 2019 Mar 13;:
Authors: Feng L, Song P, Xu F, Xu L, Shao F, Guo M, Huang W, Kong L, Wu X, Xu Q
Abstract
Psoriasis is a chronic inflammatory skin disease with unresolved pathogenesis. Studies on the pathogenesis of psoriasis have been extensively carried out, but treatments are still not satisfactory. In this study, we found improvement after treatment with cis-khellactone, a small molecular natural product, in imiquimod (IMQ)-challenged C57BL/6 mice. Cis-khellactone clearly reduced the level of cytokines in psoriatic skin, including IL-23, TNF-α, IL-1β and IL-6, while limiting inhibition of IL-17A, which is produced by Th17 cells. Cis-khellactone treatment specifically decreased dermal macrophage infiltration in psoriatic skin but not neutrophils or T cells. Additionally, compared to the control group, cis-khellactone significantly decreased the activation of NF-κB p65 in these infiltrated macrophages. Further study revealed that cis-khellactone suppressed pro-inflammatory phenotypic macrophages by promoting autophagy. Blocking autophagy by silencing Beclin1 or autophagy-related gene (Atg) 7 abrogated the effect of cis-khellactone on macrophages. The autophagy-dependent improvement in psoriasis from cis-khellactone treatment was further manifested by its limited effects on skin lesions in chloroquine (CQ)-treated mice. Moreover, cis-khellactone showed lower toxicity than MTX in macrophages and primary hepatocytes. Taken together, cis-khellactone selectively modulated macrophage function and phenotype by inducing autophagy to ameliorate psoriasis in IMQ-induced mice. Our research provides an effective strategy for the treatment of psoriasis.
PMID: 30878677 [PubMed – as supplied by publisher]
Cis-khellactone inhibited the proinflammatory macrophages via promoting autophagy to ameliorate imiquimod-induced psoriasis.
PubMed:30878677
Last Update Posted: 03/18/19 06:05AM
https://jamanetwork.com/journals/jamadermatology/article-abstract/2728095
https://www.ncbi.nlm.nih.gov/pubmed/30865237?dopt=Abstract
Using Complementary and Alternative Medicine for the Treatment of Psoriasis: A Step in the Right Direction.
JAMA Dermatol. 2019 Mar 13;:
Authors: Nwabudike LC, Tatu AL
PMID: 30865237 [PubMed – as supplied by publisher]
Using Complementary and Alternative Medicine for the Treatment of Psoriasis: A Step in the Right Direction.
PubMed:30865237
Last Update Posted: 03/14/19 06:03AM
https://clinicaltrials.gov/ct2/show/NCT02976779?type=Intr&cond=Psoriasis&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Safety Study for Future Treatment of Psoriasis
Interventions : Drug: OWC MGC cream; Drug: OWC Control Cream
Sponsor : One World Cannabis Ltd.
Completed
A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers
NCT02976779
Tue, 29 Nov 2016 12:00:00 EST
Last Update Posted: 03/13/19 10:17AM
https://clinicaltrials.gov/ct2/show/NCT03675308?type=Intr&cond=Psoriasis&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Psoriatic Arthritis
Interventions : Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor : AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308
Tue, 18 Sep 2018 12:00:00 EDT
Last Update Posted: 03/13/19 10:17AM
https://clinicaltrials.gov/ct2/show/NCT03837743?type=Intr&cond=Psoriasis&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Plaque Psoriasis
Interventions : Drug: DUR-928 Topical Solution; Drug: Vehicle Topical Solution
Sponsors : Therapeutics, Inc.; Durect
Recruiting
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
NCT03837743
Tue, 12 Feb 2019 12:00:00 EST
Last Update Posted: 03/13/19 10:17AM
https://clinicaltrials.gov/ct2/show/NCT03594877?type=Intr&cond=Psoriasis&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Psoriasis
Intervention : Dietary Supplement: Sublimated mare milk
Sponsors : Nazarbayev University Medical Center; Eurasia Invest Ltd.; Ministry of Education and Science, Republic of Kazakhstan; Centre for Dermatology and Sexually Transmitted Diseases, Astana, Kazakhstan
Recruiting
Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients
NCT03594877
Fri, 20 Jul 2018 12:00:00 EDT
Last Update Posted: 03/13/19 10:17AM
https://clinicaltrials.gov/ct2/show/NCT01687582?type=Intr&cond=Psoriasis&lupd_s=02%2F26%2F2019&lupd_d=14
Conditions : Type 2 Diabetes; Psoriasis
Intervention : Drug: GLP-1 analog
Sponsor : Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Completed
Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
NCT01687582
Wed, 19 Sep 2012 12:00:00 EDT
Last Update Posted: 03/12/19 09:59AM
https://clinicaltrials.gov/ct2/show/NCT02899962?type=Intr&cond=Psoriasis&lupd_s=02%2F25%2F2019&lupd_d=14
Condition : Psoriasis Vulgaris
Interventions : Drug: LEO 90100 aerosol foam; Drug: LEO 90100 aerosol foam vehicle
Sponsor : LEO Pharma
Active, not recruiting
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
NCT02899962
Wed, 14 Sep 2016 12:00:00 EDT
Last Update Posted: 03/11/19 10:04AM
https://clinicaltrials.gov/ct2/show/NCT03031782?type=Intr&cond=Psoriasis&lupd_s=02%2F25%2F2019&lupd_d=14
Conditions : Juvenile Psoriatic Arthritis; Enthesitis-related Arthritis
Interventions : Drug: AIN457; Other: Matched placebo
Sponsor : Novartis Pharmaceuticals
Recruiting
Secukinumab Safety and Efficacy in JPsA and ERA
NCT03031782
Thu, 26 Jan 2017 12:00:00 EST
Last Update Posted: 03/11/19 10:04AM
https://www.the-dermatologist.com/article/novel-tyk2-inhibitor-treatment-plaque-psoriasis
Novel TYK2-Inhibitor for the Treatment of Plaque Psoriasis
https://www.nejm.org/doi/10.1056/NEJMc1811317
https://www.ncbi.nlm.nih.gov/pubmed/30855749?dopt=Abstract
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.
N Engl J Med. 2019 Mar 07;380(10):981-983
Authors: Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P, Padula SJ, Thoma C
PMID: 30855749 [PubMed – in process]
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.
PubMed:30855749
Last Update Posted: 03/12/19 06:01AM
https://www.mdpi.com/1422-0067/20/5/1141
https://www.ncbi.nlm.nih.gov/pubmed/30845706?dopt=Abstract
Related Articles
Proteomics in Psoriasis.
Int J Mol Sci. 2019 Mar 06;20(5):
Authors: Chularojanamontri L, Charoenpipatsin N, Silpa-Archa N, Wongpraparut C, Thongboonkerd V
Abstract
Psoriasis has been thought to be driven primarily by innate and adaptive immune systems that can be modified by genetic and environmental factors. Complex interplay between inflammatory cytokines and T-cells, especially Th1 and Th17 cells, leads to abnormal cell proliferation and psoriatic skin lesions. Nevertheless, such mechanisms do not entirely represent the pathogenesis of psoriasis. Moreover, earlier and better biomarkers in diagnostics, prognostics, and monitoring therapeutic outcomes of psoriasis are still needed. During the last two decades, proteomics (a systematic analysis of proteins for their identities, quantities, and functions) has been widely employed to psoriatic research. This review summarizes and discusses all of the previous studies that applied various modalities of proteomics technologies to psoriatic skin disease. The data obtained from such studies have led to (i) novel mechanisms and new hypotheses of the disease pathogenesis; (ii) biomarker discovery for diagnostics and prognostics; and (iii) proteome profiling for monitoring treatment efficacy and drug-induced toxicities.
PMID: 30845706 [PubMed – in process]
Proteomics in Psoriasis.
PubMed:30845706
Last Update Posted: 03/09/19 06:00AM
https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.12866
https://www.ncbi.nlm.nih.gov/pubmed/30838736?dopt=Abstract
Progress and prospects in the management of Psoriasis and developments in Phyto-therapeutic modalities.
Dermatol Ther. 2019 Mar 05;:e12866
Authors: Daniyal M, Akram M, Zainab R, Munir N, Ali Shah SM, Liu B, Wang W, Riaz M, Jabeen F
Abstract
OBJECTIVES: The aim of this study is to review the efficacy of herbal and allopathic drugs used to manage and treat psoriasis.
METHODS: The review has been compiled using reference materials from major databases, Online Journals, Science Direct, Scopus, Open J Gate, Google Scholar and PubMed.
KEY FINDINGS: Psoriasis is a common skin disease affecting 2 – 3% of the world’s population. It is cosmetically debilitating and chronic disease which occurs both in developing and developed countries. It can affect any part of the body, but the most common sites are the elbows, knees, and scalp. It is usually treated with synthetic medicine either given systematically or applied locally. The prescribed synthetic medicines used for the treatment of psoriasis are associated with severe side effects and complications, thus researchers around the world are trying to explore new, more effective, and safer drugs from natural resources.
CONCLUSION: Medicinal plants are safe and efficacious and most of the people all over the world rely on herbal medicine due to their easy availability, low cost and efficacy for treating psoriasis. A number of medicinal plants having therapeutic potential with high efficacy used in the treatment of psoriasis have been described. Moreover, studies should be conducted to isolate and investigate the mechanism of actions of phytochemicals responsible for anti-psoriasis potential. This article is protected by copyright. All rights reserved.
PMID: 30838736 [PubMed – as supplied by publisher]
Progress and prospects in the management of Psoriasis and developments in Phyto-therapeutic modalities.
PubMed:30838736
Last Update Posted: 03/07/19 06:04AM
https://www.sciencedirect.com/science/article/pii/S0733863518311367?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/30850034?dopt=Abstract
Related Articles
What’s New in Psoriasis.
Dermatol Clin. 2019 Apr;37(2):129-136
Authors: von Csiky-Sessoms S, Lebwohl M
Abstract
Psoriasis is a common, chronic inflammatory skin disease that is characterized by the formation of sharply demarcated, scaly, erythematous plaques. It affects about 2.2% of the population in the United States and has a large impact on patient quality of life. Many advances have been made in the last few years in the management of psoriasis. Proinflammatory cytokines play major roles in the pathogenesis of disease. Biologic medications targeting the aforementioned cytokines have been developed and studied for the management of psoriatic disease. This article summarizes the newest findings in the management of psoriasis and the various treatment options available.
PMID: 30850034 [PubMed – in process]
What’s New in Psoriasis.
PubMed:30850034
Last Update Posted: 03/10/19 06:02AM
https://www.ncbi.nlm.nih.gov/pubmed/30844468?dopt=Abstract
Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study.
Diabetes Res Clin Pract. 2019 Mar 04;:
Authors: Chen P, Xu X, Lin L, Yu Y, Chen S, Chen X, Shao Z
Abstract
BACKGROUND: It has been reported that GLP-1 analogue can improve the skin lesions of psoriasis.However further research is needed to confirm that finding.
OBJECTIVE: The study can provide further data regarding the efficacy and safety of GLP-1 analogue liraglutide in the treatment of psoriasis patients with type 2 diabetes.
METHODS: We recruit 7 psoriasis patients with type 2 diabetes,and use hypodermic injection with liraglutide1.8 mg.In 12 weeks of treatment,we estimate the difference of before and after respectively,likeBMI,waist circumference,fasting blood glucose,fasting C-peptide,HbA1c,blood lipid levels,CRP,PASI,DLQI,skin tissue and pathological analysis of psoriasis.
RESULTS: After 12 weeks of treatment,the mean value of PASI decreased from 15.7±11.8 to 2.2±3.0 (P =0.03),while the DLQI decreased from 21.8±6 to 4.1±3.9 (P = 0.001).HbA1c was significantly improved after 12 weeks of treatment,decreased to 6.4±0.8% (P = 0.04),the BMI decreased to 21±3kg m-2 (P < 0.01),and the waist circumference was also significantly improved to 83±1cm (P < 0.05).And 12 weeks after , the fasting C-peptide levels increased to 1.9±0.5ng/ml (P = 0.006),HOMA - IR fell to 1.6 ±0.6 (P = 0.03).Histological analysis showed a reduction in epidermal thickness after treatment.The mean PASI decreased from 15.7 (1.5-31.3) to 2.0 (0.3-8.7) (P = 0.03),the DLQI decreased from 22 (8-27) to 4 (0-10) (P = 0.001). CONCLUSION: GLP-1 analogueliraglutide can improve the skin lesions of psoriasis patients with type 2 diabetes effectively,especially for extremely severe psoriasis patients.Its therapeutic effect may be related to anti-inflammatory,hypoglycemic and reducing weight. PMID: 30844468 [PubMed - as supplied by publisher] Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. PubMed:30844468 Last Update Posted: 03/08/19 06:03AM
https://www.dermatologytimes.com/article/promising-treatments-pipeline-psoriasis
https://www.ncbi.nlm.nih.gov/pubmed/30909325?dopt=Abstract
Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update
J Drugs Dermatol. 2019 Mar 01;18(3):229-233
Authors: Yao CJ, Lebwohl MG
Abstract
Objectives: The time that drugs for moderate-to-severe psoriasis take to see a clinically meaningful improvement (TOA) is one of the most important attributes of treatment success. This study synthesizes TOA data from previously reviewed drugs and adds clinical data for tidrakizumab and certolizumab pegol for comparison.
Methods: We reviewed published and presented efficacy data regarding TOA, which was defined as the time at which 25% of the sample population reached Psoriasis Area and Severity Index (PASI) 75 or the time at which the sample population reached a mean PASI 50.
Results: Antipsoriatic drugs obtained clinically meaningful outcomes within 1.8-25.4 w, and brodalumab had the fastest TOA for both outcome measures.
Conclusion: Brodalumab may continue to have the most rapid onset of action of available antipsoriatic therapies.
J Drugs Dermatol. 2019;18(3):229-233.
PMID: 30909325 [PubMed – as supplied by publisher]
Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update
PubMed:30909325
Last Update Posted: 03/26/19 06:04AM
https://www.ncbi.nlm.nih.gov/pubmed/30909352?dopt=Abstract
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
J Drugs Dermatol. 2019 Mar 01;18(3):297-299
Authors: Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R
Abstract
Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion were published.1,2 HP/TAZ lotion was significantly more effective than individual active ingredients or vehicle, based on improvements in Investigator’s Global Assessment (IGA), body surface area (BSA) involvement, and signs and symptoms of psoriasis (erythema, plaque elevation, and scaling) at the target lesion as well as a synergistic benefit over individual active ingredients, and good tolerability.
PMID: 30909352 [PubMed – as supplied by publisher]
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
PubMed:30909352
Last Update Posted: 03/26/19 06:04AM
https://ojs.ptbioch.edu.pl/index.php/abp/article/view/2772
https://www.ncbi.nlm.nih.gov/pubmed/30904922?dopt=Abstract
Related Articles
Genistein modulates gene activity in psoriatic patients.
Acta Biochim Pol. 2019 Feb 28;66(1):101-110
Authors: Smolińska E, Węgrzyn G, Gabig-Cimińska M
Abstract
Despite the impressive advancements in the treatment of psoriasis over the past two decades, there is still a need for further improvement. As previously shown in the literature, genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one), naturally occurring plant compound displays multidirectional action, also in relation to alleviating psoriasis symptoms. In this work we focused our attention on genistein impact on expression of genes when treating moderate-to-severe psoriasis patients. Testing the effects of this isoflavone on transcript levels in both skin specimens and peripheral blood cells of four psoriatic subjects, we found that this compound modulated activities of genes coding for anti-psoriatic members and anti-inflammatory mediators of inflammation. It impairs the activity of certain genes which are overexpressed in psoriasis, while stimulating the expression of other transcripts that are repressed in dermatosis.
PMID: 30904922 [PubMed – in process]
Genistein modulates gene activity in psoriatic patients.
PubMed:30904922
Last Update Posted: 03/25/19 01:15PM
https://www.mdmag.com/medical-news/fda-approves-selfinjection-guselkumab-for-plaque-psoriasis
https://www.centerforbiosimilars.com/news/psoriasis-guideline-antitnf-biosimilars-can-be-considered-therapeutically-interchangeable-with-references
https://clinicaltrials.gov/ct2/show/NCT03848806?type=Intr&cond=Psoriasis&lupd_s=02%2F20%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: HAT1; Drug: Calcipotriol
Sponsor : Haus Bioceuticals
Completed
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
NCT03848806
Thu, 21 Feb 2019 12:00:00 EST
Last Update Posted: 02/21/2019
Update: Completed
https://www.frontiersin.org/articles/10.3389/fmicb.2019.00236/full
https://www.ncbi.nlm.nih.gov/pubmed/30846974?dopt=Abstract
Related Articles
Crucial Role of Microbiota in Experimental Psoriasis Revealed by a Gnotobiotic Mouse Model.
Front Microbiol. 2019;10:236
Authors: Stehlikova Z, Kostovcikova K, Kverka M, Rossmann P, Dvorak J, Novosadova I, Kostovcik M, Coufal S, Srutkova D, Prochazkova P, Hudcovic T, Kozakova H, Stepankova R, Rob F, Juzlova K, Hercogova J, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z
Abstract
Psoriatic patients have altered microbiota, both in the intestine and on the skin. It is not clear, however, whether this is a cause or consequence of the disease. In this study, using an experimental mouse model of psoriasis induced by imiquimod (IMQ), we show that oral treatment with a broad spectrum of antibiotics (MIX) or metronidazole (MET) alone mitigates the severity of skin inflammation through downregulation of Th17 immune response in conventional mice. Since some antibiotics, including MET, can influence immune system reactivity, we also evaluated the effect of MIX in the same model under germ-free (GF) conditions. GF mice treated with MET did not show milder signs of imiquimod-induced skin inflammation (IISI) which supports the conclusion that the therapeutic effect is mediated by changes in microbiota composition. Moreover, compared to controls, mice treated with MIX had a significantly higher abundance of the genus Lactobacillus in the intestine and on the skin. Mice treated with MET had a significantly higher abundance of the genera Bifidobacterium and Enterococcus both on the skin and in the intestine and of Parabacteroides distasonis in the intestine. Additionally, GF mice and mice monocolonized with either Lactobacillus plantarum or segmented filamentous bacteria (SFB) were more resistant to IISI than conventional mice. Interestingly, compared to GF mice, IMQ induced a higher degree of systemic Th17 activation in mice monocolonized with SFB but not with L. plantarum. The present findings provide evidence that intestinal and skin microbiota directly regulates IISI and emphasizes the importance of microbiota in the pathogenesis of psoriasis.
PMID: 30846974 [PubMed]
Crucial Role of Microbiota in Experimental Psoriasis Revealed by a Gnotobiotic Mouse Model.
PubMed:30846974
Last Update Posted: 03/09/19 07:16AM
https://www.specialtypharmacytimes.com/news/secukinumab-demonstrates-quality-of-life-improvements-in-psoriasis-patients
https://www.ncbi.nlm.nih.gov/pubmed/30865402?dopt=Abstract
Diet and psoriasis.
Dermatol Online J. 2019 Feb 15;25(2):
Authors: Pona A, Haidari W, Kolli SS, Feldman SR
Abstract
BACKGROUND: Patients with psoriasis have a growing interest in managing their disease through diet.
OBJECTIVE: This review paper aims to analyze dietary interventions for psoriasis and their outcome.
METHODS: Terms “psoriasis AND diet” were used to search PubMed database and 63 articles describing dietary changes influencing psoriasis were selected.
RESULTS: Low calorie diet (LCD) improves Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in conjunction with topical or systemic therapy, although LCD was unsuccessful in maintaining disease remission when patients discontinued concomitant cyclosporine or methotrexate therapy. A fish oil diet improved baseline PASI of 7.7 to 5.3 at three months and 2.6 at 6 months compared to control (PASI: 8.9, 7.8, and 7.8, respectively). A randomized, double-blind, placebo-controlled study investigating selenium supplementation in psoriasis provided no PASI improvement. Zinc supplementation with concomitant betamethasone valerate 0.0025% ointment in a randomized, double-blind, placebo-controlled study provided a mean PASI of 11.2 in the intervention group and 8.0 in the control group with no significant difference between both arms. Gluten free diet and vitamin D supplementation were also efficacious dietary changes although results were mixed.
CONCLUSIONS: Dietary changes alone do not cause a large effect in psoriasis but may become an important adjunct to current first line treatments.
PMID: 30865402 [PubMed – in process]
Diet and psoriasis.
PubMed:30865402
Last Update Posted: 03/14/19 06:03AM
https://www.ncbi.nlm.nih.gov/pubmed/30865405?dopt=Abstract
A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction.
Dermatol Online J. 2019 Feb 15;25(2):
Authors: Unrue EL, Cline A, Collins A, Nguyen VH, Pelle MT, Blake P, Feldman SR
Abstract
BACKGROUND: Phototherapy is effective in treating psoriasis and other skin conditions. However, clinic-based phototherapy can be time-consuming, expensive, and inconvenient. Conventional home phototherapy addresses many hurdles, but has other limitations.
OBJECTIVE: Assess the treatment efficacy, adherence, and satisfaction of a novel ultraviolet B home phototherapy system.
METHODS: Eight patients with stable plaque psoriasis completed a multicenter, prospective, open label, interventional study using a home phototherapy device designed to improve treatment control and adherence. Matched control and study lesions were assessed on each subject. A dosing protocol based on American Academy of Dermatology guidelines for narrowband UVB phototherapy was managed by the phototherapy system. Responsiveness to the treatment was measured using the Psoriasis Severity Index (PSI) at 10 weeks versus control. Patient satisfaction was graded on a five-star Likert scale.
RESULTS: At 10 weeks, all patients experienced improvement in the treated lesions, with a mean improvement of 57% in PSI (P<0.0001 compared to baseline and P<0.0002 compared to the control lesions). Patient treatment adherence was 96% and treatment satisfaction was 100% five-star rated. Control lesions did not significantly change in PSI over the 10-week period (P=0.1411).
CONCLUSIONS: The home phototherapy system provided a safe and effective means to manage plaque psoriasis.
PMID: 30865405 [PubMed – in process]
A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction.
PubMed:30865405
Last Update Posted: 03/14/19 06:03AM
https://www.ncbi.nlm.nih.gov/pubmed/30899359?dopt=Abstract
Related Articles
Recent advances on the roles of epidermal growth factor receptor in psoriasis.
Am J Transl Res. 2019;11(2):520-528
Authors: Wang S, Zhang Z, Peng H, Zeng K
Abstract
Epidermal growth factor receptor (EGFR) is a well-characterized receptor tyrosine kinase that involved in many vital activities in cell development, such as cellular homeostasis, proliferation, division, differentiation and apoptosis. Natural activation of EGFR and the concomitant downstream signaling pathways regulation are substantial to maintain normal cellular functions. In recent studies, EGFR was demonstrated to be a fundamental modulator in the control of skin inflammatory responses. Several dermatologic diseases including psoriasis are related to the anomalous activation of EGFR signaling. It has been proved that the expression and activity of EGFR and its endogenous ligands are overexpressed in the active epidermis lesions of psoriasis. Moreover, the remarkable therapeutic improvement of chronic psoriasis in cancer patients during the treatment of EGFR inhibitors or anti-EGFR monoclonal antibodies are also recorded, suggesting that the EGFR-mediated signaling may conduct a crucial role in the pathophysiology of psoriasis.
PMID: 30899359 [PubMed]
Recent advances on the roles of epidermal growth factor receptor in psoriasis.
PubMed:30899359
Last Update Posted: 03/23/19 06:01AM
https://onlinelibrary.wiley.com/doi/abs/10.1111/sji.12742
https://www.ncbi.nlm.nih.gov/pubmed/30548969?dopt=Abstract
Related Articles
Anti-psoriatic effect of myeloid-derived suppressor cells on imiquimod-induced skin inflammation in mice.
Scand J Immunol. 2019 Mar;89(3):e12742
Authors: Kim CH, Yoo JK, Jeon SH, Lim CY, Lee JH, Koo DB, Park MY
Abstract
Myeloid-derived suppressor cells (MDSCs) play an important role in controlling the immune response against cancer and in suppression of autoimmunity and allergic inflammation. However, the beneficial effects of MDSCs on the experimental mouse model of psoriasis have not been reported. Therefore, we investigated the anti-psoriatic effect of MDSCs on IMQ-induced skin inflammation in mice and explored the mechanisms involved. Our results showed that administration of MDSCs (1 × 106 or 2 × 106 cells) suppressed the development of IMQ-induced skin inflammation in mice as exemplified by a significant reduction in clinical severity scores and was associated with a reduction of histopathological changes, including inflammatory infiltration, epidermal hyperplasia and hyperkeratosis. The immunosuppressive effect of MDSCs (1 × 106 or 2 × 106 cells) corresponded to the production of Th1 cytokines (TNF-α, IFN-γ) and Th17 cytokines (IL-17A and IL-23) in the serum and dorsal skin. Administration of MDSCs (1 × 106 or 2 × 106 cells) also inhibited splenomegaly. Moreover, an increased percentage of CD4+ CD25+ FoxP3+ regulatory T (Treg) cells and decreased percentage of Th1 and Th17 cells were found in mice treated with MDSCs. Taken together, these results imply that MDSCs have immunomodulatory and immunosuppressive effects on disease progression in a murine model of psoriasis and that MDSCs could be used in preventive or therapeutic strategies for the management of autoimmune inflammatory skin disorders, such as psoriasis.
PMID: 30548969 [PubMed – indexed for MEDLINE]
Anti-psoriatic effect of myeloid-derived suppressor cells on imiquimod-induced skin inflammation in mice.
PubMed:30548969
Last Update Posted: 03/08/19 06:03AM
https://link.springer.com/article/10.1007%2Fs13770-018-0165-3
https://www.ncbi.nlm.nih.gov/pubmed/30815354
https://www.sciencedirect.com/science/article/pii/S075333221833823X?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/30551443?dopt=Abstract
Related Articles
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.
Biomed Pharmacother. 2019 Jan;109:1876-1883
Authors: Li Y, Zhang G, Chen M, Tong M, Zhao M, Tang F, Xiao R, Wen H
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disease. As psoriasis rarely occurs in nonhuman animals, the lack of an ideal animal model reflecting the histopathological and molecular immunological characteristics of psoriasis remains an urgent issue. In the present study, an imiquimod-induced psoriasis-like dermatitis mouse model was constructed under natural immune conditions and verified by evaluations of the Psoriasis Area and Severity Index (PASI) score and Baker score, H&E staining, immunohistochemical examination of the CD3 and Gr1 levels, measurement of plasmacytoid dendritic cell- (pDC) and Th17-associated cytokine levels, and evaluation of p65 phosphorylation and TLR7 expression. Moreover, rutaecarpine (RUT), the main active ingredient in the traditional Chinese medicine Wu-Zhu-Yu, could improve psoriasis-like dermatitis through effects on pDC- and Th17-associated cytokines through NF-κB and toll-like receptor 7 (TLR7) signaling. Taken together, the imiquimod-induced psoriasis-like dermatitis mouse model can be regarded as an ideal model for evaluating psoriasis pathogenesis and antipsoriatic drugs. We provided theoretical and experimental evidence for the clinical application of RUT in psoriasis.
PMID: 30551443 [PubMed – indexed for MEDLINE]
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.
PubMed:30551443
Last Update Posted: 03/28/19 06:02AM
https://www.sciencedirect.com/science/article/pii/S0161589018305510?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/30064075?dopt=Abstract
Related Articles
Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Mol Immunol. 2018 09;101:386-395
Authors: Xie XJ, Di TT, Wang Y, Wang MX, Meng YJ, Lin Y, Xu XL, Li P, Zhao JX
Abstract
OBJECTIVES: Indirubin (IR) is a bisindole compound extracted from the leaves of Chinese herb Indigo Naturalis. Indigo Naturalis has been widely used in traditional Chinese medicine to treat inflammatory and autoimmune diseases. Psoriasis is a chronic immune-mediated inflammatory skin disease in which γδ T cells play an important role. This study aims to determine the immunoregulatory effects and the underlying mechanisms of Indirubin in psoriasis-related inflammatory responses.
METHODS: BALB/c mice with imiquimod (IMQ)-induced psoriasis-like dermatitis were treated with saline (Model), 1 mg/kg methotrexate (MTX) that serves as a positive control, or 12.5, 25 and 50 mg/kg Indirubin(IR) intragastrically. Keratinocytes proliferation, inflammatory cells infiltration, the expression of inflammatory cytokines and Jak/Stat pathway-related proteins in the skin lesion were examined. The abundance of γδ T cells in lymph nodes and spleen was determined by flow cytometry. The IL-17 expression and secretion, and the activation of Jak3/Stat3 pathways in in vitro cultured γδ T cell were tested.
RESULTS: Indirubin ameliorated keratinocyte proliferation, reduced the infiltration of CD3+ T cells, IL-17 A-producing γδ T cells, and CD11b+ neutrophils, inhibited the mRNA expression of Il1, Il6, Il23, Il17a and Il22, and the protein expression of Jak/Stat pathway-related molecules in the skin lesion. Indirubin also reduced the abundance of γδ T cell and CCR6+ γδ T cells (the major IL-17 A producer) in spleen and lymph nodes. In cultured γδ T cells, Indirubin inhibited the mRNA expression of Il17a and Ifng, and the secretion of IL-17 A, while suppressed the activation of Jak3/Stat3 pathways.
CONCLUSION: Indirubin alleviates IMQ-induced psoriasis-like dermatitis mainly through reducing the inflammatory responses mediated by IL-17 A-producing γδ T cells involving Jak3/Stat3 activation. Our results highlighted the novel mechanisms by which Indirubin ameliorates psoriasis-related inflammatory responses, supporting its therapeutic potential.
PMID: 30064075 [PubMed – indexed for MEDLINE]
Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
PubMed:30064075
Last Update Posted: 03/28/19 06:02AM
https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.13511
https://www.ncbi.nlm.nih.gov/pubmed/29427477?dopt=Abstract
Related Articles
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3.
Exp Dermatol. 2018 03;27(3):268-275
Authors: Tang L, He S, Wang X, Liu H, Zhu Y, Feng B, Su Z, Zhu W, Liu B, Xu F, Li C, Zhao J, Zheng X, Lu C, Zheng G
Abstract
The discovery of new therapeutic drugs with the efficacious and safe ability to prevent epidermal hyperplasia is extremely urgent for psoriasis. Cryptotanshinone (CTS), an active component isolated from the root of Salvia miltiorrhiza Bunge, has been reported to have antibacterial and antitumor effects. However, its effects on psoriasis have not been reported. Here, we investigated the therapeutic effects of CTS on imiquimod (IMQ)-induced psoriatic-like skin model and explored the underlying mechanisms. Our results revealed that CTS effectively alleviates IMQ-induced epidermal hyperplasia. In vitro studies also indicated that CTS potently inhibits the growth of keratinocytes. We further found that STAT3, a transcription factor for the cell growth, is the key mediator of CTS on the proliferation of keratinocytes. Taken together, our findings indicated that the curative effects of CTS on psoriasis are accomplished mainly through modulating STAT3, which providing evidences to develop CTS as a potential therapeutic agent for patients with psoriasis.
PMID: 29427477 [PubMed – indexed for MEDLINE]
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3.
PubMed:29427477
Last Update Posted: 03/21/19 06:01AM